Form 8-K - Current report:
SEC Accession No. 0001326190-24-000047
Filing Date
2024-11-12
Accepted
2024-11-12 07:09:06
Documents
16
Period of Report
2024-11-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K alt-20241112x8k.htm   iXBRL 8-K 43575
2 EX-99.1 alt-20241112xex99d1.htm EX-99.1 169488
3 GRAPHIC alt-20241112xex99d1002.jpg GRAPHIC 7092
  Complete submission text file 0001326190-24-000047.txt   377386

Data Files

Seq Description Document Type Size
4 EX-101.SCH alt-20241112.xsd EX-101.SCH 3272
5 EX-101.LAB alt-20241112_lab.xml EX-101.LAB 18717
6 EX-101.PRE alt-20241112_pre.xml EX-101.PRE 12850
18 EXTRACTED XBRL INSTANCE DOCUMENT alt-20241112x8k_htm.xml XML 4916
Mailing Address 910 CLOPPER ROAD SUITE 201S GAITHERSBURG MD 20878
Business Address 910 CLOPPER ROAD SUITE 201S GAITHERSBURG MD 20878 2406541450
Altimmune, Inc. (Filer) CIK: 0001326190 (see all company filings)

EIN.: 202726770 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-32587 | Film No.: 241443232
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)